Publicado
Acción insulínica y resistencia a la insulina: aspectos moleculares
Insulin action and resistance: molecular aspects
Palabras clave:
insulina, diabetes mellitus, metabolismo, fosforilación. (es)insulin, diabetes mellitus, metabolism, phosphorylation (en)
Las patologías asociadas a alteraciones metabólicas crónicas, como la obesidad, la diabetes y las dislipidemias; constituyen una fuente de enfermedad, muerte y discapacidad que cobra cada vez mayor relevancia en el mundo. Varios de estos problemas son consecuencia directa o indirecta de una acción insuficiente de la insulina, lo cual origina una constelación de factores de riesgo que potencian la aparición de enfermedad cardiovascular aterosclerótica en el largo plazo.
En esta revisión se abordan de manera concisa los mecanismos de acción de la insulina a nivel molecular, así como la forma en que se pueden ver afectados por factores diferentes a la constitución genética de cada individuo.
Pathologies associated with chronic metabolic disturbances like obesity, diabetes and dyslipidemia, constitute major contributors to the worldwide burden of disease, death and disability, and are acquiring a higher relevance every day. Several of these problems are a direct or indirect consequence of an insufficient action of insulin, which gives rise to a cluster of risk factors that potentiate the onset of cardiovascular atherosclerotic disease in the long term.
This review adresses in a concise way the mechanisms of insulin action at the molecular level, as well as the way they can be affected by factors different to the genetic constitution of each individual.
Referencias
Le Roith D, Zick Y. Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 2001;243:588-597.
Sierra ID: Estados metabólicos nutricionales. En: Sierra ID. Metabolismo de los carbohidratos y su importancia clínica. 2ª Ed. Bogotá: Editorial Kimpres, 1999.
Flakoll PJ, Carlson MG, Cherrington AD. Acción fisiológica de la insulina. En: Le Roith D, Taylor SI, Olefsky JM, editores. Diabetes Mellitus, Fundamentos y Clínica. 2ª ed. México: Mc Graw Hill, 2003.
Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994;43:1066-84.
Ullrich A, Bell JR, Chen EY. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 1985;313:756-61.
Shoelson SE, White MF, Kahn CR. Tryptic activation of the insulin receptor. Proteolytic truncation of the alfa-subunit releases the beta-subunit from inhibitory control. J Biol Chem 1988;263:4852-60.
Pirola L, Johnston AM, Van Obberghen E. Modulation of insulin action. Diabetologia 2004;47:170-84
Giovannone B, Scaldaferri ML, Federici M et al. Insulin receptor substrate (IRS) transduction system: distinct and overlapping signaling potential. Diabetes Metab Res Rev 2000;16:434-41.
Myers MG, White MF. The new elements of insulin signaling. Insulin receptor substrate-1 and proteins with SH2 domains. Diabetes 1993;42:643-650.
Araki E, Lipes MA, Patti ME. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 1994;372:186-90.
Tamemoto H, Kadowaki T, Tobe K. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 1994;372:182-6.
Withers DJ, Gutierrez JS, Towery H et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998;391:900-4.
Pons S, Asano T, Glasheen E et al. The structure and function of p55PIK reveals a new regulatory subunit for phosphatidylinositol 3-kinase. Mol Cell Biol 1995;15:4453-65.
Kohjiro Ueki, David A. Fruman et al. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-Kinase regulates cell signaling and survival. Mol Cell Biol 2002;22:965-77.
Currie RA, Walker KS, Gray A et al. Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase. Biochem J 1999;337:575-83.
Wada T, Sasaoka T, Funaki M et al. Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5'-phosphatase catalytic activity. Mol Cell Biol 2001;21:1633-46.
Yang C, Watson RT, Elmendorf JS et al. Calmodulin antagonists inhibit insulin-stimulated GLUT4 (glucose transporter 4) translocation by preventing the formation of phosphatidylinositol 3,4,5-trisphosphate in 3T3L1 adipocytes. Mol Endocrinol 2000;14:317-26.
Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J 1998 ;333:471-90.
Okada T, Kawano Y, Sakakibara T et al. Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. Studies with a selective inhibitor wortmannin. J Biol Chem 1994;269:3568-73.
Skolnik EY, Lee CH, Batzer A et al. The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling. EMBO J 1993;12:1929-360.
Skolnik EY, Batzer A, Li N et al. The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science 1993;260:1953-5.
Van Dam EM, Govers R, James DE. Akt activation is required at a late stage of insulin-induced GLUT4 translocation to the plasma membrane. Mol Endocrinol 2005;Publicación electrónica previa a la impresa.
Sakamoto K, Aschenbach WG, Hirshman MF et al. Akt signaling in skeletal muscle: regulation by exercise and passive stretch. Am J Physiol Endocrinol Metab 2003;285:E1081-8.
Wojtaszewski JF, Nielsen P, Kiens B et al. Regulation of glycogen synthase kinase-3 in human skeletal muscle: effects of food intake and bicycle exercise. Diabetes 2001;50:265-9.
Bhandari BK, Feliers D, Duraisamy S et al. Insulin regulation of protein translation repressor 4E-BP1, an eIF4E-binding protein, in renal epithelial cells. Kidney Int 2001;59:866-75.
Kellerer M, Coghlan M, Capp E et al. Mechanism of insulin receptor kinase inhibition in non-insulin-dependent diabetes mellitus patients. Phosphorylation of serine 1327 or threonine 1348 is unaltered. J Clin Invest 1995;96:6-11.
Grasso G, Frittitta L, Anello M et al. Insulin receptor tyrosine-kinase activity is altered in both muscle and adipose tissue from non-obese normoglycaemic insulin-resistant subjects. Diabetologia 1995;38:55-61.
Acilli D, Nakae J, Flier JS. Receptor de insulina. En: Le Roith D, Taylor SI, Olefsky JM, eds. Diabetes Mellitus, Fundamentos y Clínica. 2ª edición. México: Mc Graw Hill, 2003.
Newell AM. Genetics for targeting disease prevention: diabetes. Prim Care 2004;31:743-66 .
Freidenberg GR, Reichart D, Olefsky JMet al. Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus. Effect of weight loss. J Clin Invest 1988;82:1398-406.
Hotamisligil GS. Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes 2000;24(suppl 4):S23-S27.
Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 2003;46:15941603.
Kershaw EE, Flier JS. Adipose Tissue as an Endocrine Organ. J Clin Endocrinol Metab 2004;89:2548-56.
Garg A. Regional Adiposity and Insulin Resistance. J Clin Endocrinol Metab 2004;89:4206-4210.
Wolf G. Insulin resistance and obesity: resistin, a hormone secreted by adipose tissue. Nutr Rev 2004 Oct;62:389-94.
Schmitz-Peiffer C. Protein kinase C and lipid-induced insulin resistance in skeletal muscle. Ann N Y Acad Sci 2002;967:146-57.
Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655-7.
Standaert ML, Ortmeyer HK, Sajan MP et al. Skeletal muscle insulin resistance in obesity-associated type 2 diabetes in monkeys is linked to a defect in insulin activation of protein kinase C-zeta/lambda/iota. Diabetes 2002;51:2936-43.
Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor. Cytokine Growth Factor Rev 2003;14:447-455.
Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003;27(Suppl 3):S53-S55.
Tsao TS, Lodish HF, Fruebis J. ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol 2002;440:213-221.
Matsuzawa Y, Funahashi T, Kihara S et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:2933.
Chandran M, Phillips SA, Ciaraldi T et al. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003;26:2442-2450.
Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003;148:293-300.
Visitas a la página del resumen del artículo
Descargas
Cómo citar
Licencia
Derechos de autor 2005 Revista de la Facultad de Medicina
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
-
